Corporate calendar for Cadrenal Therapeutics, Inc. Common Stock (CVKD): upcoming earnings dates, dividend ex-dates and payment dates, stock splits, shareholder meetings and conference calls. Plan your positions around the key catalysts.
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation.
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|---|---|
| 2026-09-14 | ||
| 2026-09-14 | $563M | |
| 2026-09-14 | ||
| 2026-09-14 | $159M | |
| 2026-09-14 | $0.20 | $23M |
| 2026-09-14 |
Price
| Price | $1.08 |
| Market Cap | $4M |
| Exchange | NASDAQ |
| Country | US |
Related companies: CLGN · IBIO · ITRM · KLTO · NRSN · NRXS · RLYB
Explore sector: Healthcare · Biotechnology
More sections of CVKD: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · News
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks